Changes in urinary excretion of helical peptide during therapy for osteoporosis in older adults

Clinical Chemistry

Volumn 50, Issue 4, 2004, Pages 747-750

  Taxel, Pamela ^a   Fall, Pamela M ^a   Prestwood, Karen M ^a   Dulipsingh, Lahta ^b   Dauser, Debrorah ^a   Ohannessian, Christine ^a   Raisz, Lawrence G ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b NEW BRITAIN GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; CALCIUM CARBONATE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; ESTRADIOL; GONADORELIN AGONIST; HELICAL PEPTIDE; PEPTIDE; PLACEBO; RALOXIFENE; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; AGED; ARTICLE; BONE MATRIX; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OSTEOPOROSIS; PROSTATE CANCER; URINARY EXCRETION;

AGED; AMINO ACIDS; BIOLOGICAL MARKERS; COLLAGEN; COLLAGEN TYPE I; FEMALE; HUMANS; IMMUNOASSAY; MALE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; RANDOMIZED CONTROLLED TRIALS;

EID: 1842556137     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2003.025353     Document Type: Article

References (12)

1. Prestwood KM, Thompson DL, Kenny AM, Seibel MJ, Pilbeam CC, Raisz LG. Low dose estrogen and calcium have an additive effect on bone resorption in older women. J Clin Endocrinol Metab 1999;84:179-83.
2. Garnero P, Delmas PD. Clinical usefulness of markers of bone remodeling in osteoporosis. In: Meunier PJ, ed. Osteoporosis: diagnosis and management. London: Martin Dunitz Ltd., 1998:79-101.
3. Seibel MJ, Woitge HW, Basic principles and clinical applications of biochemical markers of bone metabolism. J Clin Densitom 1999;2:299-321.
4. Ju J, Leigh S, Byrne M, van der Rest M, Liu V, Krane S. A new marker for measuring bone resorption using an ELISA for a 14 amino acid peptide (residues 620-633) derived from the collagen α-1 chain. [Abstract]. J Bone Miner Res 1997;12(Suppl 1):S178.
5. Ju H-SJ, Maskrey J, Krane S, Riggs BL, Allen G. An immunoassay for measuring helical peptide α-1 620-633 derived form type 1 collagen α-1 chain [Abstract]. Bone 1998:23(Suppl):S629.
6. Garnero P, Delmas PD. An immunoassay for type 1 collagen α1 helicoidal peptide 620-633, a new marker of bone resorption in osteoporosis. Bone 2003;32:20-6.
7. Ju HS, Leung S, Brown B, Stringer MA, Leigh S, Scherrer C, et al. Comparison of analytical performance and biological variability of three bone resorption assays. Clin Chem 1997;43:1570-6.
8. Bonde M, Qvist P, Fledelius C, Riss BJ, Christainsen C. Immunoassay for quantifying type 1 collagen degradation products in urine evaluated. Clin Chem 1994;40:2022-5.
9. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantification of type 1 collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-8.
10. Seyedin S, Zuk R, Kung V, Daniloff Y, Shepard K. An Immunoassay to urinary pyridinoline: the new marker of bone resorption. J Bone Miner Res 1993;8:635-42.
11. Brommage R. Urinary excretion of type I collagen α1 helical peptide as a marker of bone resorption in mice. J Bone Miner Res 2002;17:S315.
12. Hannon RA, Licence RL, Chines AA, Sod EW, Eriksen EF, Eastell R. Decrease in bone resorption markers in response to risedronate: relationship to decrease in estimates of bone turnover using bone histomorphometry. J Bone Miner Res 2002;17:S270.